Circulating Tumor DNA Can Be Detected Several Years Before Cancer Diagnosis
.jpg?width=1200)
FRIDAY, June 13, 2025 -- Circulating tumor DNA can be detected more than three years prior to a clinical cancer diagnosis, according to a research brief published online May 22 in Cancer Discovery.
Yuxuan Wang, M.D., Ph.D., from the Johns Hopkins School of Medicine in Baltimore, and colleagues prospectively collected serial plasma samples from the Atherosclerosis Risk in Communities study to examine how early cancers can be detected prior to clinical signs or symptoms, including data from 26 participants diagnosed with cancer and 26 matched controls.
Eight of the 52 participants scored positively with a multicancer early detection (MCED) test at the index time point. The researchers found that within four months after blood collection, all eight participants were diagnosed with cancer. In six of these participants, an earlier plasma sample collected 3.1 to 3.5 years prior to clinical diagnosis was assessed. The same mutations detected by the MCED test could be identified in four of these six participants but at 8.6- to 79-fold lower mutant allele fractions.
"Detecting cancers years before their clinical diagnosis could help provide management with a more favorable outcome," senior author Nickolas Papadopoulos, Ph.D., from The Ludwig Center for Cancer Genetics and Therapeutics in Baltimore, said in a statement. "Of course, we need to determine the appropriate clinical follow-up after a positive test for such cancers."
Several authors disclosed ties to the biopharmaceutical industry.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Read this next
Cancer Survival Lower in Rural Areas
WEDNESDAY, Oct. 1, 2025 -- Five-year cancer survival rates for each stage of cancer (localized, regional, and distant) is lower in nonmetropolitan areas for Black and White...
Loss of Smell May Linger After COVID-19
WEDNESDAY, Oct. 1, 2025 -- Self-reported change or loss in smell or taste is an accurate signal of verified hyposmia after COVID-19, although there is also a high rate of hyposmia...
Elderly Patients Benefit From Screening Mammography
WEDNESDAY, Oct. 1, 2025 -- Patients with breast cancer diagnosed at 80 years of age or older who received screening mammography present with earlier-stage disease and have better...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.